<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27663735</article-id>
<article-id pub-id-type="pmc">5111711</article-id>
<article-id pub-id-type="publisher-id">201604992</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1604992113</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>PNAS Plus</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Immunology and Inflammation</subject>
</subj-group>
</subj-group>
<series-title>PNAS Plus</series-title>
</article-categories>
<title-group>
<article-title>Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism</article-title>
<alt-title alt-title-type="short">Neurotensin activates microglia sortilin in autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Patel</surname>
<given-names>Arti B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>Irene</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-2875-1394</contrib-id>
<name>
<surname>Leeman</surname>
<given-names>Susan E.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Theoharides</surname>
<given-names>Theoharis C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Molecular Immunopharmacology and Drug Discovery Laboratory, <institution>Department of Integrative Physiology and Pathobiology</institution>, <institution>Tufts University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff2"><sup>b</sup>Graduate Program in Cell, Molecular, and Developmental Biology, Sackler School of Graduate Biomedical Sciences, <institution>Tufts University</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff3"><sup>c</sup>Department of Pharmacology, <institution>Boston University School of Medicine</institution>, Boston, MA 02118;</aff>
<aff id="aff4"><sup>d</sup>Department of Internal Medicine, <institution>Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff5"><sup>e</sup>Department of Psychiatry, <institution>Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, <addr-line>MA</addr-line> 02111</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>theoharis.theoharides@tufts.edu</email> or <email>sleeman@bu.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Susan E. Leeman, August 9, 2016 (sent for review April 15, 2016; reviewed by Paul R. Dobner, Paul M. Hardy, and Stephen Skaper)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: A.B.P. and T.C.T. designed research; A.B.P. and I.T. performed research; A.B.P. contributed new reagents/analytic tools; A.B.P., I.T., S.E.L., and T.C.T. analyzed data; and A.B.P., S.E.L., and T.C.T. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: P.R.D., University of Massachusetts Medical School; P.M.H., Autism Research Institute; and S.S., University of Padua.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interest statement: T.C.T. has been awarded, under an agreement with Tufts University, the following patents: US 9,050,275 - Methods of Screening for and Treating Autism Spectrum Disorders and Compositions for Same and US 9,176,146 - Methods of Treating Autism Spectrum Disorders and Compositions for Same. A Provisional Patent Application was also filed by Tufts University as US 62/396,546 - Compositions and Methods of Autism Treatment. T.C.T. is also the Scientific Director of Algonot, LLC (Sarasota, FL) that has developed the flavonoid-containing trademarked dietary supplement NeuroProtek, for which Tufts receives royalties. No portion of the work described in this paper was funded by Algonot.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>8</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>9</month>
<year>2016</year>
</pub-date>
<volume>113</volume>
<issue>45</issue>
<fpage>E7049</fpage>
<lpage>E7058</lpage>
<permissions></permissions>
<self-uri xlink:href="pnas.201604992.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Human microglia, the resident immune cells of the brain, express only the neurotensin (NT) receptor-3/sortilin. NT significantly increases microglia synthesis and release of proinflammatory cytokine IL-1β and chemokine (C-X-C motif) ligand 8 (CXCL8), chemokine (C-C motif) ligand 2 (CCL2), and CCL5 via NTR3/sortilin. A soluble form of this receptor is secreted from stimulated microglia and is increased in the serum of children with autism spectrum disorders (ASD). These responses and the NT-stimulated increases in microglia numbers are mediated via mammalian target of rapamycin (mTOR) activation and are inhibitable by the natural flavonoids luteolin and methoxyluteolin.</p>
</abstract>
<abstract>
<p>We had reported elevated serum levels of the peptide neurotensin (NT) in children with autism spectrum disorders (ASD). Here, we show that NT stimulates primary human microglia, the resident immune cells of the brain, and the immortalized cell line of human microglia-SV40. NT (10 nM) increases the gene expression and release (<italic>P</italic> &lt; 0.001) of the proinflammatory cytokine IL-1β and chemokine (C-X-C motif) ligand 8 (CXCL8), chemokine (C-C motif) ligand 2 (CCL2), and CCL5 from human microglia. NT also stimulates proliferation (<italic>P</italic> &lt; 0.05) of microglia-SV40. Microglia express only the receptor 3 (NTR3)/sortilin and not the NTR1 or NTR2. The use of siRNA to target sortilin reduces (<italic>P</italic> &lt; 0.001) the NT-stimulated cytokine and chemokine gene expression and release from human microglia. Stimulation with NT (10 nM) increases the gene expression of sortilin (<italic>P</italic> &lt; 0.0001) and causes the receptor to be translocated from the cytoplasm to the cell surface, and to be secreted extracellularly. Our findings also show increased levels of sortilin (<italic>P</italic> &lt; 0.0001) in the serum from children with ASD (<italic>n</italic> = 36), compared with healthy controls (<italic>n</italic> = 20). NT stimulation of microglia-SV40 causes activation of the mammalian target of rapamycin (mTOR) signaling kinase, as shown by phosphorylation of its substrates and inhibition of these responses by drugs that prevent mTOR activation. NT-stimulated responses are inhibited by the flavonoid methoxyluteolin (0.1–1 μM). The data provide a link between sortilin and the pathological findings of microglia and inflammation of the brain in ASD. Thus, inhibition of this pathway using methoxyluteolin could provide an effective treatment of ASD.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorders</kwd>
<kwd>human microglia</kwd>
<kwd>methoxyluteolin</kwd>
<kwd>mTOR</kwd>
<kwd>sortilin</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Jane Botsford Johnson Foundation</funding-source>
<award-id rid="sp1">N/A</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">Nancy Lurie Marks Family Foundation (NLM Family Foundation)<named-content content-type="funder-id">100007429</named-content></funding-source>
<award-id rid="sp2">N/A</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>